JP2016506941A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506941A5 JP2016506941A5 JP2015555630A JP2015555630A JP2016506941A5 JP 2016506941 A5 JP2016506941 A5 JP 2016506941A5 JP 2015555630 A JP2015555630 A JP 2015555630A JP 2015555630 A JP2015555630 A JP 2015555630A JP 2016506941 A5 JP2016506941 A5 JP 2016506941A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- polymer
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 229920000642 polymer Polymers 0.000 claims 10
- 239000007788 liquid Substances 0.000 claims 9
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 229920001451 polypropylene glycol Polymers 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 230000006020 chronic inflammation Effects 0.000 claims 3
- 229940116364 hard fat Drugs 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- -1 PEG500 Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000006255 nuclear receptors Human genes 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752309P | 2013-02-04 | 2013-02-04 | |
| US61/752,309 | 2013-02-04 | ||
| PCT/EP2014/050627 WO2014117999A1 (en) | 2013-02-04 | 2014-01-14 | Compositions and methods for treating chronic inflammation and inflammatory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506941A JP2016506941A (ja) | 2016-03-07 |
| JP2016506941A5 true JP2016506941A5 (enExample) | 2017-02-16 |
| JP6474352B2 JP6474352B2 (ja) | 2019-02-27 |
Family
ID=50150686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555630A Active JP6474352B2 (ja) | 2013-02-04 | 2014-01-14 | 慢性炎症及び炎症性疾患を治療する組成物と方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2950821A1 (enExample) |
| JP (1) | JP6474352B2 (enExample) |
| KR (1) | KR20150129664A (enExample) |
| CN (1) | CN105120900A (enExample) |
| AU (1) | AU2014211715B2 (enExample) |
| BR (1) | BR112015015870B1 (enExample) |
| CA (1) | CA2898017A1 (enExample) |
| HK (1) | HK1218621A1 (enExample) |
| IL (1) | IL239920A0 (enExample) |
| MX (1) | MX366317B (enExample) |
| RU (1) | RU2680801C2 (enExample) |
| SG (1) | SG11201505243PA (enExample) |
| WO (1) | WO2014117999A1 (enExample) |
| ZA (1) | ZA201505006B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| EP3313519B1 (en) * | 2015-06-29 | 2023-05-31 | Children's Medical Center Corporation | Jak-stat inhibitors for the treatment of congenital myopathies |
| CN108283637A (zh) * | 2018-04-04 | 2018-07-17 | 无锡市儿童医院 | 辛伐他汀的应用 |
| WO2019195943A1 (en) * | 2018-04-13 | 2019-10-17 | Urban Juve Provisions Inc. | Cannabis root extract, method of manufacture, method of use |
| CN114555103A (zh) * | 2019-06-03 | 2022-05-27 | 伊美诺路克斯国际公司 | 用于治疗疾病的天花疫苗和干细胞 |
| CN114615974B (zh) * | 2019-11-06 | 2025-01-03 | 智能科技专题有限公司 | 环加氧酶抑制剂的局部制剂及其用途 |
| RU2749857C1 (ru) * | 2019-12-23 | 2021-06-17 | Псарева Нелли Александровна | Способ борьбы со средним и наружным отитом |
| RU2752764C1 (ru) * | 2020-12-14 | 2021-08-03 | Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") | Фармацевтическая композиция, обладающая противовоспалительным действием |
| WO2022207580A2 (en) | 2021-03-27 | 2022-10-06 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| RU2760220C1 (ru) * | 2021-06-02 | 2021-11-22 | Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) | Способ определения клинически значимой усталости у больного ревматоидным артритом на фоне 5-летней терапии базисными противовоспалительными препаратами или базисными противовоспалительными препаратами в комплексе с генно-инженерными биологическими препаратами и/или психофармакотерапией и сопутствующего расстройства тревожно-депрессивного спектра |
| WO2025122472A1 (en) * | 2023-12-04 | 2025-06-12 | Primus Pharmaceuticals, Inc. | Emollient compositions comprising linoleic acid and conjugated linoleic acid and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143934A (en) * | 1990-11-21 | 1992-09-01 | A/S Dumex (Dumex Ltd.) | Method and composition for controlled delivery of biologically active agents |
| GB9613858D0 (en) * | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
| DK0999826T3 (da) * | 1997-07-29 | 2004-07-26 | Upjohn Co | Selv-emulgerende formulering til lipofile forbindelser |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US8663692B1 (en) * | 1999-05-07 | 2014-03-04 | Pharmasol Gmbh | Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same |
| BR0010354A (pt) * | 1999-05-07 | 2002-03-05 | Pharmasol Gmbh | Partìculas de lipìdeo à base em misturas de lipìdeos lìquidos e sólidos e método para a sua produção |
| CN1173695C (zh) * | 1999-06-14 | 2004-11-03 | 科斯默股份公司 | 控制释放与掩蔽味道的口服药物组合物 |
| US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| WO2005009436A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| CN101065115A (zh) * | 2004-11-24 | 2007-10-31 | 默克公司 | 取代酰胺的液体和半固体口服药物制剂 |
| US20060138059A1 (en) | 2004-12-28 | 2006-06-29 | Vair Larry L Jr | Corona-treated polypropylene liquid filtration media |
| AU2006240551A1 (en) * | 2005-04-28 | 2006-11-02 | Dsm Ip Assets B.V. | Pharmaceutical dosage forms comprising a lipid phase |
| US20070249725A1 (en) * | 2006-02-17 | 2007-10-25 | Hubbard David R | Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain |
| GB0704846D0 (en) * | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| WO2009153496A2 (fr) | 2008-05-26 | 2009-12-23 | Genfit | Composés agonistes ppar, préparation et utilisations |
| JP2014507429A (ja) * | 2011-02-04 | 2014-03-27 | バイオコピア リミテッド | 心血管疾患の治療のための組成物および方法 |
-
2014
- 2014-01-14 SG SG11201505243PA patent/SG11201505243PA/en unknown
- 2014-01-14 BR BR112015015870-6A patent/BR112015015870B1/pt active IP Right Grant
- 2014-01-14 WO PCT/EP2014/050627 patent/WO2014117999A1/en not_active Ceased
- 2014-01-14 AU AU2014211715A patent/AU2014211715B2/en active Active
- 2014-01-14 RU RU2015137659A patent/RU2680801C2/ru active IP Right Revival
- 2014-01-14 CN CN201480006334.8A patent/CN105120900A/zh active Pending
- 2014-01-14 MX MX2015009058A patent/MX366317B/es active IP Right Grant
- 2014-01-14 KR KR1020157020598A patent/KR20150129664A/ko not_active Withdrawn
- 2014-01-14 JP JP2015555630A patent/JP6474352B2/ja active Active
- 2014-01-14 CA CA2898017A patent/CA2898017A1/en not_active Abandoned
- 2014-01-14 HK HK16106607.4A patent/HK1218621A1/zh unknown
- 2014-01-14 EP EP14705479.5A patent/EP2950821A1/en not_active Withdrawn
-
2015
- 2015-07-13 ZA ZA2015/05006A patent/ZA201505006B/en unknown
- 2015-07-14 IL IL239920A patent/IL239920A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506941A5 (enExample) | ||
| JP2016504401A5 (enExample) | ||
| JP2016504403A5 (enExample) | ||
| JP2018526351A5 (enExample) | ||
| JP2016508155A5 (enExample) | ||
| Maury et al. | Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome | |
| JP2013510123A5 (enExample) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| RU2017115772A (ru) | Комбинация для генотерапии | |
| RU2015139758A (ru) | Хиназолины в качестве ингибиторов киназы | |
| MX2018002631A (es) | Inhibidores de molecula pequeña de dyrkia y usos de los mismos. | |
| EP3355874A4 (en) | TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2017528503A5 (enExample) | ||
| PE20160550A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| CO6700827A2 (es) | Corticosteroides para el tratamiento de dolor de articulaciones | |
| HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
| JP2014505733A5 (enExample) | ||
| CL2013003333A1 (es) | Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras. | |
| WO2009053741A3 (en) | Novel formulation | |
| HRP20180121T1 (hr) | Donori nitroksila s poboljšanim terapijskim indeksom | |
| MX387217B (es) | Composiciones de solución sólida para aines. | |
| EA201070783A1 (ru) | 1,2,4-оксадизольные соединения для лечения аутоиммунных заболеваний | |
| JP2018537513A5 (enExample) | ||
| WO2015116856A3 (en) | Farnesoid x receptor antagonists |